XML 94 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Share-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Summary of Share-based Compensation Under Each Plan According to Change in Estimate
The table below shows the share-based compensation by plan:
Share-based compensation - expenseYear ended
(in € thousands)2021/12/312022/12/312023/12/31
SO 2018186 — — 
SO US 201824 — — 
AGA S 201939 50 — 
AGA D 201916 6 — 
SO 2019105 (21)— 
SO 2019 - US(11)(16)— 
BSA 2019— — — 
SO US 2019(7)— — 
SO D 202014 14 14 
SO C 202040 40 40 
SO US 202019 19 (7)
AGA S 202129 32 34 
AGA D 20215 7 7 
SO D 20212 13 12 
SO C20219 55 50 
SO US 20212 9 9 
AGA S 2022— 11 49 
AGA D 2022— 2 11 
SO D 2022— 4 18 
SO C 2022— 17 83 
SO US 2022— 4 18 
SO SU 2022— — 4 
AGA S 2023— — 47 
AGA D 2023— — 12 
SO D 2023— — 31 
SO C 2023— — 104 
SO US 2023— — 27 
SO SU 2023— — 16 
TOTAL470 245 578 
Share Warrants  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Summary of Key Terms and Conditions of Share-Based Compensation Based
Share warrants (BSA)20192017
BSA 2019BSA 2017-ABSA 2017-B
Option pricing modelBlack Scholes
Fair value per IFRS 2€0.75 €3.78 €3.81 
Issue price€1.23 €2.00 €2.00 
Exercise price€12.32 €19.97 €19.97 
Expected volatility40.0 %36.4 %35.7 %
End of exercise period2024/05/312022/06/302022/07/15
Expected dividends0 %0 %0 %
Risk free interest rate0 %0 %0 %
Conversion ratio1:11:11:1
Free Shares  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Summary of Key Terms and Conditions of Share-Based Compensation Based
The following table summarizes the data relating to free shares and the assumptions used for the measurement thereof, in accordance with IFRS 2—Share-based Payment:
Free Shares (AGA)
2023
202220212019
AGA D & S
2023
AGA D & S
2022		AGA S
2021		AGA D
2021		AGA D & S
2019
Option pricing modelMonte Carlo
Fair value per IFRS 2
€4.05
€4.08 €4.00 €4.15 €17.06 
Grant date03/10/202310/14/202203/30/202103/17/202107/18/2019
Share price at grant date
€4.05
€4.08 €4.00 €4.15 €17.06 
Expected volatility84.3 %50 %51 %51 %40.2 %
Vesting period
From 03/10/2023
to 03/13/2026
From 10/14/2022 to 10/16/2025
From 03/30/2021 to 03/31/2024
From 03/17/2021 to 03/31/2024
From 07/18/2019 to 09/16/2022
Expected dividends0 %0 %0 %0 %0 %
Risk free interest rate3.06 %2.24 %-0.59 %-0.59 %0 %
Conversion ratio
1:1
1:11:11:11:1
Expected employee turnover0 %0 %0 %0 %0 %
Information on free shares activity is as follows for 2022:
Grant DateTypeAGAs
issued		AGAs
outstanding as of January 1, 2022		AGAs awardedAGAs vestedAGAs cancelled/ forfeitedAGAs
outstanding as of December 31, 2022
10/14/2022
AGA S 202239,20039,20030038,900
10/14/2022
AGA D 202220,00020,00020,000
03/30/2021
AGA S 202132,40029,0002,70026,300
03/17/2021
AGA D 202115,00015,00015,000
07/18/2019
AGA S 201917,55610,78210,7820
07/18/2019
AGA D 201919,07013,0688,7124,3560
TOTAL67,85059,20019,4947,356100,200
Stock Options  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Summary of Key Terms and Conditions of Share-Based Compensation Based
The following tables summarize the data relating to stock options and the assumptions used for the measurement thereof, in accordance with IFRS 2—Share-based Payment:
Stock options (SO)
2023
SO SU 2023
SO D 2023
SO C 2023
SO US 2023
Option pricing modelBlack Scholes
Fair value per IFRS 2
€2.39
€2.19
€2.39
€2.19
Grant date3/13/20233/13/20233/13/20233/13/2023
Share price at grant date€4.00€4.00€4.00€4.00
Exercise price
€3.26
€4.07
€3.26
€4.05
Expected volatility83.74 %83.74 %83.74 %83.74 %
Vesting period
From 03/13/2023 to 03/13/2026
Exercise periodFrom 03/14/2023 to 03/13/2033
Expected dividends0 %0 %0 %0 %
Risk free interest rate2.75 %2.75 %2.75 %2.75 %
Conversion ratio1:11:11:11:1
Expected employee turnover0 %0 %0 %0 %
Stock options (SO)20222021
SO SU 2022SO D 2022SO C 2022SO US 2022SO D 2021SO C 2021SO US 2021
Option pricing modelBlack Scholes
Fair value per IFRS 2€1.40 €1.57 €1.90 €1.56 €1.06 €1.30 €1.07 
Grant date12/2/202210/17/202210/17/202210/17/202210/20/202110/20/202110/20/2021
Share price at grant date€3.46 €4.16 €4.16 €4.16 €3.24 €3.24 €3.24 
Exercise price€2.95 €3.91 €3.12 €3.94 €3.26 €2.61 €3.22 
Expected volatility49.0 %50.0 %50.0 %50.0 %50.0 %50.0 %50.0 %
Vesting periodFrom 3/12/2022 to 3/12/2025
From 17/10/2022 to 17/10/2025
From 20/10/2021 to 20/10/2024
Exercise periodFrom 3/12/2022 to 3/12/2032
From 18/10/2025 to 17/10/2032
From 21/10/2024 to 21/10/2031
Expected dividends0 %0 %0 %0 %0 %0 %0 %
Risk free interest rate2.1 %2.24 %2.24 %2.24 %-0.6 %-0.6 %-0.6 %
Conversion ratio1:11:11:11:11:11:11:1
Expected employee turnover0 %0 %0 %0 %0 %0 %0 %

Stock options (SO)20202019
SO D 2020SO C 2020SO US 2020SO 2019SO US 1 2019SO US 2 2019
Option pricing modelBlack Scholes
Fair value per IFRS 2€1.16 €1.46 €1.12 €4.59 €3.67 €3.23 
Grant date12/31/202012/31/202012/31/20207/18/20197/18/201911/27/2019
Share price at grant date€3.99 €3.99 €3.99 €17.06 €17.06 €14.50 
Exercise price€4.38 €3.50 €4.52 €13.99 €16.90 €14.31 
Expected volatility49.0 %49.0 %49.0 %40.0 %40.0 %40.0 %
Vesting period
From 31/12/2020 to 31/12/2023
From 18/07/2019 to 16/09/2022
From 27/11/2019 to 16/01/2023
Exercise period
From 01/01/2024 to 31/12/2027
From 17/09/2022 to 17/09/2029
From 17/01/2023 to 17/01/2030
Expected dividends0.0 %0.0 %0.0 %0.0 %0.0 %0.0 %
Risk free interest rate-0.7 %-0.7 %-0.7 %0.0 %0.0 %0.0 %
Conversion ratio1:11:11:11:11:11:1
Expected employee turnover0 %0 %0 %0 %0 %0 %

Stock options (SO)201820172016
SO 2018SO US 2018SO 2017SO 2016
Option pricing modelBlack Scholes
Fair value per IFRS 2€9.32 €6.90 €9.32 €10.30 
Grant date11/7/201811/7/201812/6/201712/15/2016
Share price at grant date€22.10 €22.10 €21.95 €20.79 
Exercise price€16.00 €21.65 €17.91 €15.79 
Expected volatility44.1 %44.1 %53.7 %63.0 %
Vesting period
From 07/11/2018 to 31/12/2021
From 06/12/2017 to 31/12/2020
From 15/12/2016 to 15/12/2019
Exercise period
From 01/01/2022 to 31/12/2028
From 01/01/2021 to 31/12/2027
From 16/12/2019 to 16/12/2026
Expected dividends0 %0 %0 %0 %
Risk free interest rate0.0 %0.0 %0.0 %0.0 %
Conversion ratio1:11:11:11:1
Expected employee turnover15 %15 %15 %15 %
In 2019, the Group revised its estimate of the number of equity instruments expected to be vested taking into account the number of lapsed instruments noted after 4 years of successive plans. As a result, GENFIT revised the turnover rate assumption, which was estimated at 15%, to a rate of 0%, taking into account recent observations and the actual number of lapsed instruments at each closing.
Definitive vesting is subject to continued employment with the Group and performance conditions.
Information on stock options activity is as follows for 2023:
Grant DateTypeSO
issued
SO outstanding as of January 1, 2023
SO awardedSO cancelled/ forfeitedSO exercised
SO outstanding
as of December 31, 2023
SO exercisable
as of December 31, 2023
03/13/2023
SO SU 2023
16,30016,30016,300
03/13/2023
SO D 2023
35,00035,00035,000
03/13/2023
SO C 2023
108,700108,700108,700
03/13/2023
SO US 2023
30,20030,20030,200
02/12/2022
SO SU 20228,7508,7508,7500
10/17/2022SO D 202235,00035,00035,0000
10/17/2022SO C 2022131,000131,000131,0000
10/17/2022SO US 202234,62534,62534,6250
10/20/2021SO D 202135,00035,00035,0000
10/20/2021SO C 2021134,375124,3754,000120,3750
10/20/2021SO US 202132,50025,00025,0000
12/31/2020SO D 202035,00035,00035,00035,000
12/31/2020SO C 2020103,75081,25081,25081,250
12/31/2020SO US 202056,25050,00022,50027,50027,500
07/18/2019SO 2019107,88051,34351,34351,343
07/18/2019SO US 1 201930,6205,1135,1135,113
11/07/2018SO 2018122,00068,32968,32968,329
11/07/2018SO US 201817,5009,7139,7139,713
12/06/2017SO 2017-164,16443,21243,21243,212
12/06/2017SO 2017-232,08617,76517,76517,765
12/15/2016SO 2016-141,91734,39834,39834,398
12/15/2016SO 2016-220,95815,30815,30815,308
TOTAL805,181190,20026,5000968,881388,931
Information on stock options activity is as follows for 2022:
Grant DateTypeSO
issued		SO outstanding as of January 1, 2022SO awardedSO cancelled/ forfeitedSO exercisedSO outstanding
as of December 31, 2022		SO exercisable
as of December 31, 2022
02/12/2022
SO SU 20228,7508,7508,7500
10/17/2022SO D 202235,00035,00035,0000
10/17/2022SO C 2022131,000131,000131,0000
10/17/2022SO US 202234,62534,62534,6250
10/20/2021SO D 202135,00035,00035,0000
10/20/2021SO C 2021134,375134,37510,000124,3750
10/20/2021SO US 202132,50025,00025,0000
12/31/2020SO D 202035,00035,00035,0000
12/31/2020SO C 2020103,75081,25081,2500
12/31/2020SO US 202056,25050,00050,0000
07/18/2019SO 2019107,88077,01525,67251,34351,343
07/18/2019SO US 1 201930,6207,6702,5575,1135,113
11/07/2018SO 2018122,00068,32968,32968,329
11/07/2018SO US 201817,5009,7139,7139,713
12/06/2017SO 2017-164,16443,21243,21243,212
12/06/2017SO 2017-232,08617,76517,76517,765
12/15/2016SO 2016-141,91734,39834,39834,398
12/15/2016SO 2016-220,95815,30815,30815,308
TOTAL634,035209,37538,2290805,181245,181
Performance Conditions  
Disclosure of terms and conditions of share-based payment arrangement [line items]  
Summary of Key Terms and Conditions of Share-Based Compensation Based
Performance conditions of 2023 plans
PlansNature of performance conditions
SO D 2023
SO C 2023
SO US 2023
SO SU 2023
AGA S 2023
AGA D 2023

Evaluation date for performance conditions:
3/13/2026
Internal conditions - a) 50% of the instruments SO D 2023/SO C 2023/SO US 2023/ SO SU 2023/AGA S 2023 will be exercisable or definitively vest, and 5,000 of the Free Shares for the AGA D 2023 will be vest, if during 2023 and then at any time during the Vesting Period, 2 new R&D programs (at the rate of one-half of these 2023 instruments per new program), join the Company’s R&D pipeline (as evaluated at December 31, 2022) ; and that these programs are at the clinical development stage at the time they join the pipeline or that they later enter this stage, following: (i) A business development transaction (in-licensing, M&A, etc.) or, (ii) Identification of new opportunities resulting from in-house research (program going from preclinical development stage to clinical development stage). b) 25% of the instruments SO D 2023/SO C 2023/SO US 2023/ SO SU 2023/AGA S 2023 will be exercisable or definitively vest, and 2,500 of the Free Shares for the AGA D 2023 will vest, if at least one of the two following conditions related to development of elafibranor in PBC is met: (i) Filing of the Marketing Authorization Application in the fourth quarter of 2023 (in Europe or the United States); (ii) Marketing Authorization obtained in 2024 (in Europe or the United States). c) 15% of the instruments SO D 2023/SO C 2023/SO US 2023/ SO SU 2023/AGA S 2023 will be exercisable or definitively vest, and 1,500 of the Free Shares for the AGA D 2023 will vest, if at least one of the two following conditions related to the development of the ACLF program is met: (i) VS-01 in ACLF: top-line results from the Phase 2 study obtained in 2024 or communication of final results on the Phase 2 study in 2025; (ii) NTZ : start of a Phase 2 clinical trial in the second half of 2023. d) 10% of the instruments SO D 2023/SO C 2023/SO US 2023/ SO SU 2023/AGA S 2023 will be exercisable or definitively vest, and 1,000 of the Free Shares for the AGA D 2023 will vest, if intermediate results in the Phase 1b/2 of GNS561 are obtained in the fourth quarter 2024 or final results obtained in 2025.
External conditions - Each applicable portion of all 10,000 Free Shares under the AGA D 2023 plan, as each Internal Conditions above is met, is then subject to the External Condition according to the methods described below. The degree of fulfillment of the External Condition relating to the Company's stock market price will be determined according to the relative performance of GENFIT shares. Each applicable portion of all 10,000 Free Shares under the AGA D 2023 plan, as each Internal Conditions above is met, will be definitively acquired per the following conditions: (a) No AGA D 2023 shall vest if the Final Price is strictly lower than the Initial Price; (b) If the Final Price is between (i) a value equal to or greater than the Initial Price and (ii) a value lower than the Ceiling Price, the number of AGA D 2023 definitively allocated will be equal to: [(Final Price / Initial Price) -1] x 1/2 of the number of AGA D 2023 instruments (c) All AGA D 2023 if the Final Price is equal to or higher than the Ceiling Price. The notions of “Final Price”, “Initial Price” and “Ceiling Price” are defined in the plan regulations.

Performance conditions of 2022 plans
PlansNature of performance conditions
SO D 2022
SO C 2022
SO US 2022
SO SU 2022
AGA S 2022
AGA D 2022

Evaluation date for performance conditions:
- 10/17/2025 for SO D 2022/SO C 2022/SO US 2022/AGA S 2022/AGA D 2022
- 12/3/2025 for SO SU 2022
Internal conditions - a) 50% of the instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 10,000 of the Free Shares for the AGA D 2022 will vest, if during the 2022 financial year and then at any time during the Vesting Period, 3 new R&D programs (at the rate of one third of these 2022 instruments per new program) complete the Company's R&D program portfolio (as it was at 12/31/2021); that these programs are at the so-called clinical development stage when this addition is made or that they reach this stage afterwards and that this addition originates: (i) a business-development operation (licensing-in, M&A, etc.), or (ii) the identification of new opportunities resulting from internal research (repositioning). b) 25% of the instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 5,000 of the Free Shares for the AGA D 2022 will vest, if at least one of the following three conditions relating to the development of the elafibranor development program is fulfilled: (i) obtaining the main results of the first part of the ELATIVE® trial in the second quarter of 2023; (ii) filing of a Marketing Authorization Application for elafibranor in the second half of 2023; (iii) marketing authorization for elafibranor in 2024. c) 15% of the instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 3,000 of the Free Shares for the AGA D 2022 will vest, if at least one of the following two conditions relating to the development of the NTZ program in the ACLF is fulfilled: (i) First clinical results in 2022; (ii) Start of a Phase 2 clinical trial in the first half of 2023. d) 10% of instruments SO D 2022/SO C 2022/SO US 2022/ SO SU 2022/AGA S 2022 will be exercisable or definitively vest, and 2,000 of the Free Shares for the AGA D 2022 will vest, if as part of the development of the GNS561 program, a Phase 2b trial starts in the first half of 2023.
External conditions - Each applicable portion of all 20,000 Free Shares under the AGA D 2022 plan, as each Internal Conditions above is met, is then subject to the External Condition according to the methods described below. The degree of fulfillment of the External Condition relating to the Company's stock market price will be determined according to the relative performance of GENFIT shares. Each applicable portion of all 20,000 Free Shares under the AGA D 2022 plan, as each Internal Conditions above is met, will be definitively acquired per the following conditions: (a) No AGA D 2022 shall vest if the Final Price is strictly lower than the Initial Price; (b) If the Final Price is between (i) a value equal to or greater than the Initial Price and (ii) a value lower than the Ceiling Price, the number of AGA D 2022 definitively allocated will be equal to:[(Final Price / Initial Price) -1] x 1/2 of the number of AGA D 2022 instruments (c) All AGA D 2022 if the Final Price is equal to or higher than the Ceiling Price. The notions of “Final Price”, “Initial Price” and “Ceiling Price” are defined in the plan regulations.